Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
T EisenS Ashley

Abstract

We previously developed an inpatient regimen that consisted of infusional fluorouracil (5-FU), epirubicin, and cisplatin (ECisF), with a response rate of 86% in advanced breast cancer. The current phase II 2:1 randomized study investigated whether cyclophosphamide can be substituted for cisplatin (ECycloF) to reduce toxicity and allow the regimen to be administered on an outpatient basis without loss of efficacy. Ninety-six women (median age, 49 years; range, 28 to 73) with breast cancer (59 metastatic, 37 locally advanced) received continuous infusional 5-FU (200 mg/m2/d via Hickman line) and six cycles of epirubicin (60 mg/m2 every 21 days) with either cyclophosphamide 600 mg/m2 every 21 days (38 metastatic, 24 locally advanced) or cisplatin 60 mg/m2 every 21 days (21 metastatic, 13 locally advanced). There were no significant differences in patient characteristics between these groups. ECycloF was better tolerated than ECisF in terms of lethargy (P = .005), stomatitis (P = .008), plantar palmar erythema (P = .02), constipation (P < .001), thrombosis (P = .0014), and nausea and vomiting (P = .05). Although there was a trend toward more anemia and leukopenia with ECisF (P =. 1), there was no significant difference in the rates...Continue Reading

Citations

Nov 12, 1998·Journal of the National Cancer Institute·A GoldhirschH J Senn
Jan 18, 2012·Chemotherapy·Ali I Shamseddine, Fadi S Farhat
Jun 24, 2017·The Cochrane Database of Systematic Reviews·Sam J EggerNicholas Wilcken
Apr 27, 2007·Virchows Archiv : an International Journal of Pathology·Ossama TawfikCarol J Fabian
Nov 15, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sonia SengMatthew D Galsky
Nov 3, 2016·Breast Cancer Research and Treatment·Fausto PetrelliSerena Di Cosimo
Jun 24, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B SirohiI E Smith
Dec 8, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M A VolleberghS C Linn

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Danny RischinLester Peters
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
B F El-RayesP A Philip
© 2022 Meta ULC. All rights reserved